Eris Lifesciences · NSE: ERIS · BSE: 540596
Q4 FY20 results · Jan–Mar 2020
Eris Lifesciences reported revenue from operations of ₹248.57 crore (up 15.7% from Q4 FY19) and net profit of ₹56.27 crore (up 4.4% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 248.57 | 214.82 | +15.7% | 266.40 | −6.7% |
| Other income | (1.07) | 11.73 | Turned loss | 8.47 | Turned loss |
| Total income | 247.50 | 226.55 | +9.2% | 274.87 | −10.0% |
| Profit before tax | 61.50 | 58.24 | +5.6% | 72.16 | −14.8% |
| Net profit for the period | 56.27 | 53.88 | +4.4% | 63.47 | −11.3% |
| EPS, basic (₹) | 4.13 | 3.93 | +5.1% | 4.62 | −10.6% |
| Net margin (%) | 22.6 | 25.1 | 23.8 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 230.74 | 198.43 | +16.3% | 254.27 | −9.3% |
| Other income | (0.80) | 11.60 | Turned loss | 7.91 | Turned loss |
| Total income | 229.94 | 210.03 | +9.5% | 262.18 | −12.3% |
| Profit before tax | 59.22 | 59.10 | +0.2% | 71.01 | −16.6% |
| Net profit for the period | 55.11 | 52.42 | +5.1% | 62.68 | −12.1% |
| EPS, basic (₹) | 4.05 | 3.81 | +6.3% | 4.55 | −11.0% |
| Net margin (%) | 23.9 | 26.4 | 24.6 |
Consolidated
- Filed with BSE
- 27 Jun 2020, 14:04 IST
- Board meeting
- 26 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jun 2020, 14:04 IST
- Board meeting
- 26 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE